IGMS - IGM Biosciences Inc Stock Price, Fair Value and News

$1.27

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IGMS Price Action

Last 90 days

7.6%

Trailing 12 Months

-86.3%

IGMS RSI Chart

IGMS Valuation

Market Cap

77.9M

Price/Earnings (Trailing)

-1.46

Price/Sales (Trailing)

26.75

EV/EBITDA

-0.25

Price/Free Cashflow

-0.49

IGMS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IGMS Fundamentals

IGMS Revenue

Rev. Growth (Yr)

11.4K%

Rev. Growth (Qtr)

49.73%

IGMS Earnings

Earnings (TTM)

-53.4M

Earnings Growth (Yr)

303.72%

Earnings Growth (Qtr)

284.5%

IGMS Profitability

EBT Margin

-6709.90%

Return on Equity

-52.89%

Return on Assets

-49.9%

Free Cashflow Yield

-203.8%

IGMS Investor Care

Shares Dilution (1Y)

1.46%

Diluted EPS (TTM)

-0.9

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	2.1M	2.9M	2.9M	0
2023	1.3M	1.6M	1.9M	2.1M
2022	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About IGM Biosciences Inc

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

CEO	Mr. Fred M. Schwarzer J.D.
WEBSITE	https://igmbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	289

IGM Biosciences Inc Frequently Asked Questions

What is the ticker symbol for IGM Biosciences Inc? What does IGMS stand for in stocks?

IGMS is the stock ticker symbol of IGM Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of IGM Biosciences Inc (IGMS)?

As of Fri Aug 15 2025, market cap of IGM Biosciences Inc is 77.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IGMS stock?

You can check IGMS's fair value in chart for subscribers.

Is IGM Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether IGMS is over valued or under valued. Whether IGM Biosciences Inc is cheap or expensive depends on the assumptions which impact IGM Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IGMS.

What is IGM Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Aug 15 2025, IGMS's PE ratio (Price to Earnings) is -1.46 and Price to Sales (PS) ratio is 26.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IGMS PE ratio will change depending on the future growth rate expectations of investors.